Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity
Parker J. Jamieson, Xiaoying Shen, Alexandra A. Abu-Shmais, Perry T. Wasdin, Katarzyna Janowska, Robert J. Edwards, Garrett Scapellato, Maurice Bukenya, Lindsay E Bass, Simone I. Richardson, Nelia P. Manamela, Shuying Liu, Maggie Barr, Lindsey Adams, Cristina Paola Velez-Castro, , Ivelin S. Georgiev
The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.
Journal of Virology · Nov 10, 2025Peer-reviewedImmunology